Alnylum

- Work of scientists with Regulus, Alnylam and ETH Zurich shows microRNAs 103/107 are upregulated in mouse models of obesity; targeting with anti-miRs improves glucose homeostasis and insulin sensitivity -

LA JOLLA, Calif., and CAMBRIDGE, Mass., June 8, 2011 /PRNewswire/ — Regulus Therapeutics Inc., a biopharmaceutical company leading the discovery and development of innovative medicines targeting microRNAs, and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, today announced the publication in Nature of new pre-clinical data in mice about the antagonism of microRNA-103 and microRNA-107 (miR-103/107). Data from a collaborative study performed by Regulus, Alnylam and ETH Zurich demonstrated that antagonism of miR-103/107 with proprietary chemically modified anti-miR oligonucleotides could promote insulin signaling in both liver and adipose tissue.  Silencing miR-103/107 in animal models of obesity improved glucose homeostasis, suggesting that these microRNAs are potential targets for the treatment of diabetes.

Defects in insulin signaling are among the most common and earliest defects that predispose an individual to the development of type 2 diabetes. The new findings demonstrated that miR-103/107 are upregulated in obese mice, and silencing with anti-miRs could improve glucose homeostasis and insulin sensitivity, while gain of function in liver or fat caused impaired glucose homeostasis. Direct targets of miR-103/107 identified include [click to continue…]

Incoming search terms for this article:

{ 0 comments }

Industry Press Update

by Chris on February 17, 2011

in Press Release

02/17/2011 – 09:00 AM
miRagen Therapeutics Receives Orphan Drug Designation for MGN-4893 for the Treatment of Polycythemia Vera

02/10/2011 – 04:00 PM
Alnylam to Webcast Conference Call Discussing Fourth Quarter and 2010 Financial Results

02/10/2011 – 08:30 AM
Regulus Therapeutics to Present Multiple Platform and Pipeline Advancements at the Keystone Symposium on microRNAs

02/08/2011 – 04:00 PM
Alnylam to Webcast Presentation at the 13th Annual BIO CEO & Investor Conference

01/27/2011 – 07:15 AM
RXi Pharmaceuticals Announces Positive Initial Results in microRNA Therapeutics

01/25/2011 – 08:00 AM
Alnylam Receives Positive Opinion for Orphan Drug Designation from European Medicines Agency for ALN-TTR01, an RNAi Therapeutic for the Treatment of Transthyretin-Mediated Amyloidosis

01/25/2011 – 07:30 AM
NanoString Technologies Introduces Multiplexed Assay Kit for Mouse microRNA Analysis

{ 0 comments }

Industry Press

by Chris on January 18, 2011

in News

1/18/2011 – 01:45 PM

miRagen Therapeutics Named University of Colorado Technology Transfer Office Bioscience Company of the Year

01/18/2011 – 08:00 AM

Mirna Therapeutics and Collaborators Publish New Data on miR-34 and its Role in Cancer Stem Cells

01/12/2011 – 02:00 PM

Asuragen Announces New Notices of Allowance from USPTO Related to the Diagnostic Applications of Cancer-Related miRNAs at the JP Morgan Healthcare Conference

01/06/2011 – 07:30 AM

Alnylam Launches “Alnylam 5×15” Product Strategy and Provides Guidance and Goals for 2011

01/05/2011 – 12:30 PM

Research and Markets: Biochips – Technologies, Markets and Companies – Updated Report with Projected Value to 2015 and 2020

01/05/2011 – 08:30 AM

Regulus Therapeutics Promotes Garry E. Menzel, Ph.D., to Chief Operating Officer and Executive Vice President of Finance

01/04/2011 – 03:27 PM

Research and Markets: RNAi – An Updated Report on Technologies, Markets and Companies

01/04/2011 – 07:30 AM

Alnylam Demonstrates RNAi in Man with Systemically Delivered RNAi Therapeutics

{ 0 comments }

Targeting a Master Regulator of Disease

by Chris on July 7, 2010

in News

Drugmakers place big bets on the emerging science of microRNA.

By Arlene Weintraub

San Diego startup Regulus, founded in 2007, has quietly been working on a new way to target RNA for drug development. The company has been studying a subset of RNA molecules called microRNAs, or miRNAs. First discovered in the 1990s, misbehaving miRNAs have been linked to several diseases, including cancer and heart failure. Drug developers hope these molecules will prove to be particularly effective drug targets because manipulating just one seems to suppress several disease-linked proteins–whereas most biotech drugs only target individual proteins. [click to continue…]

{ 0 comments }

Business Wire 1/25/09

The newly allowed claims cover miR-21, a microRNA that has been linked to a variety of diseases, including cancer, fibrosis, and heart disease. The claims additionally encompass single-stranded and double-stranded antisense compounds complementary to miR-21. The allowance of this second Tuschl III patent in the U.S. extends the scope of this patent estate, which has already yielded patents directed to miR-122 in the U.S. (U.S. Patent No. 7,232,806), Australia (Australia Patent No. 2002 347 035), and Japan (Japan Patent No. 4 371 812). (read more…)

{ 0 comments }